Maximilian Kloft

AI-powered tools are rapidly emerging across cancer research and clinical practice. Looking forward to our discussion on "How to Evaluate and Collaborate on AI-Powered Tools in Oncology" at the ESMO #YO4YO session. 4 May 15:00 - 16:00 CEST @myESMO @GuiNaderMarta @Rodrosb

How to proceed from conference abstracts to high-impact publications in #thoraciconcology ? 🔬 Great @myESMO #ELCC2026 mentorship session by #youngoncologists with wonderful mentors @pompili_cecilia and @DrAlexAdjei, thank you for your insights! @mkmoutafi @DrHongchengZhu

A successful starting #ESMOYOC event of #ELCC26 with Vesalius talk for finding the your niche in thoracic oncology by @stephanieplsaw 🇸🇬 @NReguart 🇪🇸 @BenjaminBesseMD 🇫🇷 @DoctorJSpicer 🇨🇦 Excellent insights deserve #YoungOncologists to learn from our international experts 🤩

Day 2 of #ELCC26 @myESMO was a blast! 💥 Great insights at the #ESMOYOC Mentorship Session “From trainee to thoracic oncologist: Building your career roadmap” with @peters_solange and @gerryhanna. Thank you 👏 Stay tuned and follow YOCs in the upcoming session!

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced GC/GEJ cancer @TheLancetOncol doi.org/10.1016/S1470-… 🔎 KYM901 phs 1 trial 👉ORR 29%, DCR 68% 👉SAE ≥3 68% 👉first CLDN18.2- specific ADC 🧐Phs 3 ongoing... @myESMO

Am heutigen Holocaust-Gedenktag wie an jedem anderen Tag: #WeRemember. Die Stolpersteine vor unserem Eingang erinnern uns täglich daran, was sich nicht wiederholen darf.

Vivek Subbiah (@VivekSubbiah) shares the Top Phase 1 clinical trial publications of 2024 oncodaily.com/url/217361 #Cancer #ClinicalTrials #Phase1trials #PrecisionOncology #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

🔥off the press: Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma @ESMO_Open authors.elsevier.com/sd/article/S20… 👉🎯💊are effective in BTC 🤨Access to 💊 is a global problem with unacceptable disparities btw countries 🧐We urgently need new approval & reimbursment strategies to provide global access to effective therapies @myESMO @EASLnews @ILCAnews @curecc #livertwitter

Artificial intelligence as a tool to identify predictive biomarker in immuno-oncology: this systematic review by @PrelajArsela and coll. in Annals of Oncology encompasses genomics, radiomics, pathomics, real-world and multimodal data annalsofoncology.org/article/S0923-…

Important talk from @sautesfridm about an under-researched topic in oncology. #ESMO23

Historical moment for GU oncology. @tompowles1 brilliantly presents the results of the EV-302 phase 3 trial, showing a doubling of OS for patients with mUC receiving 1L enfortumab vedotin+pembro vs SoC platinum-based chemo. ADCs keep shining and improving outcomes! #ESMO23